The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes

StatusUnknown
PhasePhase 2
Started

Record status This record was last updated March 12, 2024 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Mar 2024); last known: Recruiting
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a prospective, single center, single-arm, phase 2 study. The aim of this study is to evaluate the efficacy and safety of Luspatercept for Patients with Lower-risk Myelodysplastic Syndromes (MDS).
Trial Details
NCT Number NCT05925504
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Collaborators: Beijing Health Alliance Charitable Foundation
Conditions
(from sponsor)		 Lower Risk MDS Per IPSS-R
Enrollment 36 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov